Genentech, a member of the Roche Group (SWX: ROP; OTCMKTS: RHHBY), announced new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart compared with a sham procedure that mimics intravitreal (IVT) injections in adults with uveitic macular edema (UME). Across both studies, the data continue to support the potential for rapid and sustained improvements in vision and reductions in macular thickness — swelling in the back of the eye due to retinal fluid — with vamikibart treatment.
Clinical Trial Milestone
| Item | Detail |
|---|---|
| Company | Genentech, a member of the Roche Group (SWX: ROP; OTCMKTS: RHHBY) |
| Product | Vamikibart – investigational anti‑IL‑6 monoclonal antibody for intravitreal administration |
| Studies | Phase III MEERKAT and SANDCAT |
| Population | Adults with uveitic macular edema (UME) |
| Comparator | Sham procedure mimicking intravitreal (IVT) injection |
| Data Timepoint | One year |
| Key Findings | Rapid and sustained vision improvements; reductions in macular thickness (specific values not disclosed) |
| Announcement Date | 10 Oct 2026 |
Drug Profile & Mechanism of Action
- Molecule: Vamikibart, an investigational monoclonal antibody.
- Route: Specifically engineered for intravitreal (IVT) administration — direct delivery into the eye.
- Target: Interleukin‑6 (IL‑6), a key cytokine in the inflammatory pathway driving UME.
- Mechanism Rationale: By neutralizing IL‑6 locally in the eye, vamikibart aims to interrupt the inflammatory cascade that increases vascular permeability and leads to fluid accumulation in the macula.
- Earlier Clinical Evidence: In the Phase I DOVETAIL study, vamikibart provided rapid vision improvements and resolution of macular edema in people with UME — the foundation for the Phase III program.
Clinical Evidence – Phase III MEERKAT & SANDCAT
| Endpoint | Result (Vamikibart) | Comparator (Sham) | Notes |
|---|---|---|---|
| Vision Improvement | Rapid and sustained improvement across both studies at one year | Sham | Specific values not disclosed |
| Macular Thickness Reduction | Sustained reductions in macular thickness (retinal fluid–driven swelling) | Sham | Specific values not disclosed |
| Safety Profile | Not disclosed | – | – |
MEERKAT and SANDCAT are Phase III studies in adults with uveitic macular edema, each comparing vamikibart against a sham procedure designed to mimic IVT injections, preserving blinding. The one-year dataset is consistent with the rapid-onset signal first observed in Phase I DOVETAIL and extends it to sustained efficacy over 12 months. Patient numbers, site counts, secondary endpoints, and safety data were not detailed in the announcement.
Disease & Treatment Context – Uveitic Macular Edema
- Uveitis and Its Complication: Uveitis — inflammation of the uvea, the eye’s middle layer — can extend to retinal vasculature, and macular edema is a leading cause of vision loss in affected patients.
- Pathophysiology: Inflammatory cytokines, with IL‑6 prominent among them, disrupt the blood-retinal barrier, allowing fluid to accumulate in the macula and degrade central vision.
- Current Management: UME has historically been managed with corticosteroids (local or systemic) and immunomodulatory therapy, approaches often constrained by steroid-related ocular and systemic side effects with chronic use.
- Targeted Alternative Concept: An IL‑6–directed antibody engineered for intravitreal delivery offers a non-steroidal, pathway-specific strategy with the potential for durable control of edema between administrations.
Market Impact & Outlook
- Late-Stage Momentum: One-year Phase III data across two pivotal studies keep vamikibart on track as a potential first targeted anti‑IL‑6 therapy for UME; regulatory filing plans and timelines were not disclosed.
- Roche Ophthalmology Portfolio: The program extends Genentech/Roche’s leadership position in retinal disease, adding an inflammatory eye disease asset to a franchise built on anti‑VEGF therapies.
- Unmet Need: Patients with UME lacking durable, steroid-sparing options represent a defined population for a sustained-effect intravitreal biologic.
- Competitive Landscape: UME therapy development remains limited relative to other retinal indications; a successful vamikibart approval could establish a new pharmacologic standard.
- Next Steps: Continued follow-up of MEERKAT and SANDCAT and any future submission discussions with regulators were not detailed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding vamikibart, including the interpretation of one-year MEERKAT and SANDCAT data and its potential in uveitic macular edema. Vamikibart is investigational and not approved in any jurisdiction. Actual results may differ due to risks including further data maturation, safety findings, regulatory review outcomes, and competitive dynamics.-Fineline Info & Tech
